Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.

MLA

Geerlinks, Ashley V., et al. “Alemtuzumab and CXCL9 Levels Predict Likelihood of Sustained Engraftment after Reduced-Intensity Conditioning HCT.” Blood Advances, vol. 7, no. 14, July 2023, pp. 3725–34. EBSCOhost, https://doi.org/10.1182/bloodadvances.2022009478.

APA

Geerlinks, A. V., Scull, B., Krupski, C., Fleischmann, R., Pulsipher, M. A., Eapen, M., Connelly, J. A., Bollard, C. M., Pai, S.-Y., Duncan, C. N., Kean, L. S., Baker, K. S., Burroughs, L. M., Andolina, J. R., Shenoy, S., Roehrs, P., Hanna, R., Talano, J.-A., Schultz, K. R., … Marsh, R. A. (2023). Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood Advances, 7(14), 3725–3734. https://doi.org/10.1182/bloodadvances.2022009478

Chicago

Geerlinks, Ashley V, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A Pulsipher, Mary Eapen, James A Connelly, et al. 2023. “Alemtuzumab and CXCL9 Levels Predict Likelihood of Sustained Engraftment after Reduced-Intensity Conditioning HCT.” Blood Advances 7 (14): 3725–34. doi:10.1182/bloodadvances.2022009478.